

D1 dopamine receptor hyperphosphorylation in renal proximal tubules in hypertension

P Yu¹, LD Asico¹, Y Luo¹, P Andrews¹, GM Eisner¹, U Hopfer², RA Felder³ and PA Jose¹

¹Georgetown University Medical Center, Washington, Distr. Columbia, USA; ²Case Western Reserve University School of Medicine, Cleveland, Ohio, USA and ³University of Virginia Health Sciences Center, Charlottesville, Virginia, USA

A defect in the coupling of the D₁ receptor (D₁R) to its G protein/effector complex in renal proximal tubules plays a role in the pathogenesis of spontaneous hypertension. As there is no mutation of the D₁R gene in the spontaneously hypertensive rat (SHR), we tested the hypothesis that the coupling defect is associated with constitutive desensitization/phosphorylation of the D₁R. The following experiments were performed: (1) Cell culture and membrane preparations from rat kidneys and immortalized rat renal proximal tubule cells (RPTCs); (2) immunoprecipitation and immunoblotting; (3) cyclic adenosine 3',5' monophosphate and adenylyl cyclase assays; (4) immunofluorescence and confocal microscopy; (5) biotinylation of cell surface proteins; and (6) *in vitro* enzyme dephosphorylation. Basal serine-phosphorylated D₁Rs in renal proximal tubules, brush border membranes, and membranes from immortalized RPTCs were greater in SHRs (21.0 ± 1.5 density units, DU) than in normotensive rats (7.4 ± 2.9 DU). The increased basal serine phosphorylation of D₁Rs in SHRs was accompanied by decreased expression of D₁R at the cell surface, and decreased ability of a D₁-like receptor agonist (fenoldopam) to stimulate cyclic adenosine 3',5' monophosphate (cAMP) production. Increasing protein phosphatase 2A activity with protamine enhanced the ability of fenoldopam to stimulate cAMP accumulation (17 ± 4%) and alter D₁R cell surface expression in intact cells from SHRs. Alkaline phosphatase treatment of RPTC membranes decreased D₁R phosphorylation and enhanced fenoldopam stimulation of adenylyl cyclase activity (26 ± 6%) in SHRs. Uncoupling of the D₁R from its G protein/effector complex in renal proximal tubules in SHRs is caused, in part, by increased D₁R serine phosphorylation.

Kidney International (2006) **70**, 1072–1079. doi:10.1038/sj.ki.5001708; published online 19 July 2006

KEYWORDS: D₁ receptor (D₁R); serine phosphorylation; protein phosphatase activity

Correspondence: P Yu, Division of Pediatric Nephrology, Department of Pediatrics, Georgetown University Medical Center, 3800 Reservoir Road, NW, Washington, DC 20007-2197, USA. E-mail: yup@georgetown.edu

Received 19 September 2005; revised 14 April 2006; accepted 9 May 2006; published online 19 July 2006

Dopamine receptors in the central nervous system and peripheral tissues have been implicated in the regulation of blood pressure.^{1,2} Dopamine exerts its action via two families of dopamine receptors that belong to the superfamily of G protein-coupled receptors (GPCR). The D₁-like receptor family (D_{1A} and D_{1B} in rodents, D₁ and D₅ in humans) is linked to stimulation of adenylyl cyclase, via the stimulatory G protein, G_{αs}. The D₂-like receptor family (D₂, D₃, and D₄) is linked to inhibition of adenylyl cyclase, via the inhibitory G proteins, G_{αi} and G_{αo}. There are remarkable parallels in the abnormal dopamine signaling, via D₁-like receptors, in rodent models of genetic hypertension (e.g., spontaneously hypertensive rat (SHR)) and human essential hypertension. Disruption of either one of the D₁-like receptors (D₁ or D₅) in mice leads to the development of hypertension.^{3,4} D₁-like receptor inhibition of NHE3, Na⁺/HCO₃⁻, Cl⁻/HCO₃⁻, and Na⁺/K⁺ATPase activities in the renal proximal tubule and medullary thick ascending limb of Henle is impaired in the SHR and Dahl salt-sensitive rat.^{1,2,5-7} The impaired D₁-like receptor inhibitory effect on renal sodium transport in hypertension has been shown to be caused, in part, by impaired production of cytoplasmic second messengers.^{1,2,5-7}

Despite the impairment of D₁-like receptors to exert their agonist effects in hypertension, there are no mutations in the coding region of the D₁R or D₅R in patients with essential hypertension or in genetically hypertensive rats.⁸ Instead, in hypertension, the D₁R in the renal proximal tubule and medullary thick ascending limb of Henle is uncoupled from its G protein/effector complex,⁵⁻¹⁰ a state that is associated with increased basal phosphorylation of the D₁R.^{8,11} This finding is of interest because the functional status of dopamine receptors is determined, in part, by their state of phosphorylation, a process common to members of the GPCR superfamily.¹²⁻¹⁴ Agonist occupation of GPCRs results in generation of second messengers, receptor phosphorylation, and desensitization causing a decrease in GPCR responsiveness to subsequent agonist stimulation.¹³⁻¹⁵ Upon removal of the agonist, the attenuated responsiveness of the receptor is reversed by a dephosphorylation process subserved by protein phosphatases, probably of the 2A or 2B type, in the case of D₁-like receptors.¹⁶⁻¹⁸ The dephosphorylation leads to cell surface membrane recycling and resensitization of GPCRs.

We have reported that the uncoupling of the D₁R in renal proximal tubules in the SHR may be a consequence of a defective resensitization process, caused by decreased activity of protein phosphatase_{2A} (PP_{2A}).¹⁶ However, the phosphorylation state and the cell surface membrane localization of the D₁R in kidneys of SHRs have not been reported. Therefore, the current studies were designed to determine the phosphorylation state and subcellular distribution of D₁ receptors (D₁Rs) in renal proximal tubules of WKY and SHRs. As the D₁R is phosphorylated at serine residues,^{8,11,14,15,19,20} we measured the amount of serine-phosphorylated D₁Rs in renal cortical and brush border membranes (BBMs), and immortalized renal proximal tubule cells (RPTCs). In addition, we determined whether increasing protein phosphatase activity by pretreatment of cell membranes with the catalytic subunit of alkaline phosphatase^{21,22} or increasing PP_{2A} activity in intact RPTCs, by protamine,^{12,23,24} can enhance D₁R function in SHRs.

RESULTS

Phosphorylation of D₁Rs

To determine the extent of phosphorylation of the D₁R, *ex vivo* and *in vitro* studies were performed using freshly obtained rat kidney cortices, freshly prepared BBMs, and immortalized RPTCs because renal D₁Rs are predominantly located in proximal tubules.^{1,7–11,16,25–31} Moreover, the D₁R defect in spontaneous hypertension has been well characterized in renal proximal tubules.^{1–3,5,7–11,16,25–27,32} Basal levels of serine-phosphorylated D₁R were greater in renal cortical membranes, BBMs, and immortalized RPTCs from SHRs than from WKY rats (Figure 1, Table 1). The D₁-like agonist, fenoldopam, increased the quantity of serine-phosphorylated D₁R in WKY rats but not in SHRs (Figure 1, Table 1). Pretreatment with carbidopa (renal cortical membranes and BBMs) had no effect on basal serine phosphorylation of D₁Rs (not shown). Therefore, the results from the non-treated and treated groups were pooled together.

Distribution of D₁Rs in RPTCs

In order to determine the relative subcellular distribution of D₁Rs, we studied immortalized RPTCs in culture. Using live cells labeled with a cell-impermeant and non-cleavable biotin (sulfo-*N*-hydrosuccinamide (NHS)-biotin) reagent,^{25,32} we found that the cell surface membrane fluorescence intensity was greater in WKY than in SHRs (Figure 2a). The cell

surface membrane proteins (red) and D₁Rs (green) showed extensive colocalization (yellow) in cells from WKY rats, but were markedly reduced in cells from SHRs. Indeed, most of D₁Rs were internal to the cell surface membranes in SHRs.

We also compared the fluorescence intensity in permeabilized and non-permeabilized cells.

The D₁R can be visualized in non-permeabilized cells because the polyclonal D₁R antibody recognizes the third extracellular loop of the receptor. In non-permeabilized cells, fluorescence intensity was again greater in WKY than in SHRs (Figure 2b). However, after cell permeabilization, the total cellular expression of D₁Rs was similar in WKY and SHRs (Figure 2b), consistent with our previous report that the expression of D₁Rs, quantified by immunoblotting, in renal cortex or in RPTCs was similar in WKY and SHRs.¹⁰

To verify the visual impression of decreased cell surface membrane D₁Rs in RPTCs from SHRs, cells were cultured in Transwells to maintain apical and basolateral polarity. Cell surface membrane proteins were biotinylated with cell impermeant and non-cleavable sulfo-NHS-biotin,




Figure 1 | Serine phosphorylation of D₁Rs in membranes from rat kidney cortex, brush border membranes (BBM) from rat kidney, and immortalized RPTCs from WKY and SHRs. Membranes were prepared as described in 'Supplementary text'. Membrane proteins were subjected to immunoprecipitation with monoclonal anti-phosphoserine antibodies and immunoblotting with polyclonal anti-D₁R antibodies as described in 'Materials and Methods'. The immunoreactive bands (≈ 70 – 80 kDa) were quantified by densitometry. WC and SC, controls from WKY and SHR cells, respectively; WF and SF, fenoldopam-treated cells from WKY and SHRs, respectively. Results are expressed as mean \pm s.e.m., $n = 4$ – 5 /group, * $P < 0.05$ vs other groups except for cells from SHRs treated with D₁-like agonist, ANOVA, Newman-Keuls test. Inset is one of 4–5 independent immunoblots.

Table 1 | Serine-phosphorylated D₁Rs in cortical and BBMs from kidneys and immortalized RPTCs from WKY and SHRs were quantified by co-immunoprecipitation/immunoblotting as described in 'Materials and Methods'

	Kidney cortex		BBM		RPTC	
	WKY	SHR	WKY	SHR	WKY	SHR
Control/vehicle	7 \pm 3*	21 \pm 1.5	8 \pm 4*	36 \pm 4	14 \pm 1.9*	31 \pm 2.2
Fenoldopam (5 μ M)	55 \pm 3	17 \pm 6	25 \pm 4	31 \pm 5	38 \pm 2.1	24 \pm 3.5

ANOVA Student–Newman–Keuls, * $P < 0.05$, WKY control vs WKY fenoldopam-treated and SHR control, $n = 4$ – 5 .

The results in density units from Figure 1 are shown.

Abbreviations: BBMs, brush border membranes; D₁Rs, D₁ receptors; RPTC, renal proximal tubule cell.




Figure 2 | Distribution of D₁Rs in immortalized RPTCs from WKY and SHRs. (a) Cellular distribution of D₁Rs in live cells. Cellular distribution was determined with cell-impermeant, non-cleavable biotin-labeling of live cells examined with double immunofluorescence confocal microscopy, as described in 'Materials and Methods'. Confocal images showed biotin-labeled membrane proteins as red color, and the D₁R as green color. The colocalization was seen as a yellow color in 'merge'. The image is one of at least three separate experiments. Bar = 20 μ m. (b) Cellular distribution of D₁Rs by immunofluorescence. Non-permeabilized RPTCs from WKY rats had greater immunofluorescence than in SHRs. After permeabilization, fluorescence intensities were similar in the two rat strains. (c) Quantitation of D₁Rs on surface membranes of RPTCs from WKY and SHRs. The quantity of D₁Rs in apical and basolateral membranes was determined by biotinylation of proteins at the surface membranes of RPTCs grown on Transwells, as described in 'Materials and Methods'. D₁R density at the apical membranes was greater in WKY (67.8 ± 4.4 DU) than in SHRs (32.1 ± 4.7 DU). In contrast, D₁R density was greater at the basolateral membranes in SHRs (67.1 ± 4.5 DU) than in WKY rats (33.8 ± 4.6 DU) ($P < 0.01$, ANOVA Newman-Keuls test, $n = 5$). Inset is one immunoblot.

immunoprecipitated with anti-D₁R antibodies, and immunoblotted with avidin-conjugated peroxidase (Figure 2c). D₁R abundance at the apical membranes was greater in cells from WKY rats (67.8 ± 4.4 density units, DU) than those from SHRs (32.1 ± 4.7 DU) (Figure 2c), corroborating the immunofluorescence studies in Figure 2a and b. In contrast, D₁Rs were mainly located at basolateral membranes in cells from SHRs (67.1 ± 4.5 DU) relative to cells from WKY rats (33.8 ± 4.6 DU). Comparison of protein abundance in BBMs between WKY and SHRs is not precise because proteins can be redistributed within renal brush border microvilli³³ and D₁Rs are present in both brush border and subapical membranes.

We next studied the immunohistochemistry of rat kidney sections. We found that the cellular distribution of D₁Rs in renal cortical tubules was different between WKY and SHRs. In the renal cortex of WKY rats, D₁Rs were mainly located at

microvillous brush border and apical membranes. In contrast, in SHRs, D₁Rs were distributed throughout the cytosol with minimal expression at brush border and apical membranes (Figure 3). Therefore, the kidney section studies confirmed the results obtained in immortalized RPTCs (Figure 2a, b and c). We also stained for rab GTPase 5 (Rab5), a marker protein for early or sorting endosome. Rab5-positive endosomes have been shown to serve as sorting compartments for both receptor recycling and degradation pathways.^{34–36} Several studies have shown that internalized GPCRs, such as the β_2 -adrenergic receptor, and the AT₁R, colocalize with Rab5 in endocytic vesicles.^{35,36} We found that in the kidney cortex, Rab5 was distributed throughout the cytosol in both rat strains. However, some Rab5 expression was also observed in apical membranes in WKY. In contrast, the colocalization of D₁R with Rab5 in small vesicles (yellow color) in SHRs was mainly located at the basal membranes




Figure 3 | Colocalization of D₁R with Rab5 in proximal tubules from rat kidney sections. Double immunofluorescence staining was performed as described in 'Materials and Methods'. The cellular distribution of D₁Rs in renal cortical tubules was different between WKY and SHRs. In WKY rats, D₁Rs (red color) were mainly located at microvillous brush border and apical membranes. In contrast, in SHRs, D₁Rs were distributed throughout the cytosol with minimal expression at brush border and apical membranes. Rab5 (green color) was distributed throughout the cytosol in both rat strains. However, some Rab5 expression was also observed in apical membranes in WKY. In contrast, in SHRs, the colocalization of D₁R with Rab5 in small vesicles (yellow color) was mainly located at the basal membranes. The image from transmitted light (DIC, differential interference contrast) is shown in gray. The image is one of the three separate experiments. Bar = 20 μm.

(Figure 3). The results indicated that more D₁Rs colocalized in Rab5-positive compartment vesicles in SHRs relative to WKY rats under basal conditions.

Effect of protamine on cAMP accumulation and distribution of D₁Rs

In preliminary studies, we found that the D₁R co-immunoprecipitated with PP_{2A} catalytic subunit (PP_{2AC}) but not with PP₁ or PP_{2B} in both WKY and SHRs (data not shown). The data indicated that PP_{2A} may directly interact with D₁R and that PP_{2A} may play a more important role than other protein phosphatases in D₁R regulation. PP_{2A} has been reported to be important in the dephosphorylation and resensitization of the D₁R.^{16,17} Whereas, a D₁R agonist (fenoldopam) increased PP_{2A} activity in renal proximal tubules from WKY rats, PP_{2A} activity was decreased by fenoldopam in SHRs.¹⁶ We next determined the consequences of protamine treatment on D₁R-mediated increase in cAMP accumulation and membrane expression of D₁Rs. Protamine has been shown to stimulate PP_{2A} activity but inhibit PP₁ activity.^{12,23,24} We found that pretreatment of immortalized RPTCs with protamine overnight increased PP_{2A} activity by 77 ± 5.5% in WKY and 91.5 ± 11.8% in SHRs. Basal (control) cAMP levels in immortalized RPTCs were higher in WKY rats (282 ± 30 pmol/mg protein/20 min) than in SHRs (123 ± 18 pmol/mg protein/20 min, *n* = 4-5/group, *P* < 0.05 *t*-test). Protamine increased fenoldopam-induced cAMP accumulation in RPTCs from SHRs (17 ± 4%) (Figure 4a) to the same degree observed in RPTCs from WKY rats (24 ± 3%). These studies suggested that increasing PP_{2A} activity, and presumably the dephosphorylation of the D₁R, restored D₁R responsiveness to agonist stimulation in SHRs (see below).

Agonist-induced internalization of D₁R has been reported in many cell lines and types.^{15,37,38} In our studies in RPTCs from WKY rats, fenoldopam stimulation resulted in more D₁R expression at the surface of one pole of the cell (observed under non-permeabilized conditions). The areas that lacked D₁R on the cell surface of non-permeabilized cells were probably the areas where the D₁R got internalized (with fenoldopam treatment) and therefore, could not be detected by fluorescence microscopy under non-permeabilized conditions. The D₁Rs were internalized by 64 ± 4% in RPTCs from WKY rats. In contrast, fenoldopam did not induce internalization of D₁Rs in RPTCs from SHRs (1.0 ± 1.1%, *P* < 0.01, *n* = 3) (Figure 4b). However, protamine pretreatment enabled fenoldopam to internalize more D₁Rs on the cell surface membranes of RPTCs from SHR (45.5 ± 5.8%) (Figure 4b), indicating that protamine allowed expression of D₁Rs on the cell surface that were then internalized with fenoldopam stimulation. It is also possible that recruitment of D₁Rs at one cell surface pole was increased by fenoldopam in WKY rats and that the recruitment was improved by protamine treatment in SHRs. Fenoldopam has been reported to increase the recruitment of D₁Rs to cell surface membranes of LLCPK1 cells.³⁹

Effect of pretreatment of RPTC membranes with alkaline phosphatase on the ability of D₁-like receptor stimulation of adenylyl cyclase activity

To confirm the results obtained with protamine, we determined the effect of alkaline phosphatase treatment on adenylyl cyclase activity in RPTC membranes from SHRs. This method has been used to show the importance of dephosphorylation on the ability of natriuretic peptide receptor B to stimulate guanylyl cyclase activity.²² Basal




Figure 4 | Effect of protamine treatment on cAMP accumulation and cellular distribution of D₁Rs in immortalized RPTCs from WKY and SHRs. (a) Cells were treated with vehicle (control) or the D₁-like agonist, fenoldopam, in the presence or absence of protamine as described in 'Supplementary text'. In RPTCs from SHRs not treated with protamine, fenoldopam did not increase cAMP accumulation ($-5.8 \pm 4.1\%$ increase from control). After protamine treatment, fenoldopam increased cAMP accumulation in RPTCs from SHRs ($+45 \pm 13\%$ to the same degree as those observed in RPTCs from WKY rats ($+64 \pm 21.1\%$) ($n = 4-5$ group, $*P < 0.05$ vs fenoldopam, paired t -test). (b) Effect of protamine on the cellular distribution of D₁Rs in RPTCs from SHRs. The cells, grown on coverslips, were treated with protamine as in (a), and immunofluorescence was studied under non-permeabilized conditions. Fenoldopam ($5 \mu\text{mol/l}/10 \text{ min}$) increased D₁R expression at one pole of WKY cells ($64 \pm 4\%$, top panel) but not in SHR cells ($1.0 \pm 1.1\%$, $P < 0.01$, $n = 3$) (middle panel). Protamine treatment of SHR cells enabled fenoldopam to increase D₁R expression at one pole of SHR cells (bottom panel) ($45.5 \pm 5.8\%$). The image is one of at least three separate experiments. Bar = $10 \mu\text{m}$.

adenylyl cyclase activity was similar in RPTCs from SHRs and WKY (52.4 ± 8.0 and $55.5 \pm 18.9 \text{ pmol/mg/min}$). (Note: the greater basal cAMP levels in intact RPTCs from WKY rats than in SHRs may be due to the fact that receptor recycling from the cytosol to the cell surface membranes could not




Figure 5 | Effect of alkaline phosphatase (AP) treatment on adenylyl cyclase activity and serine phosphorylation of D₁Rs in membranes of immortalized RPTCs from WKY and SHRs. (a) Effect of alkaline phosphatase on adenylyl cyclase activity. Membrane proteins from RPTCs were incubated with alkaline phosphatase as described as in 'Materials and Methods'. Fenoldopam ($5 \mu\text{mol/l}/10 \text{ min}$) did not increase adenylyl cyclase activity in RPTCs from SHRs. Pretreatment of the membranes for 20 min with alkaline phosphatase enabled fenoldopam to increase adenylyl cyclase activity in RPTCs from SHRs ($*P < 0.05$, vs fenoldopam, paired t -test, $n = 6$). (b) Effect of AP on D₁R phosphorylation in SHRs. Some of the RPTC membrane proteins from SHRs (Figure 4a) were lysed in TBSN buffer (see Materials and Methods) and subjected to immunoprecipitation with anti-phosphoserine antibody as in Figure 1. Alkaline phosphatase treatment decreased the basal phosphorylation of D₁Rs and increased the fenoldopam-induced phosphorylation of D₁Rs (similar to those noted in RPTCs from WKY rats – see Figure 1).

occur in membranes.) Fenoldopam ($5 \mu\text{mol/l}/10 \text{ min}$) increased adenylyl cyclase activity in RPTCs from WKY ($50 \pm 10\%$ from control), but not in RPTCs from SHRs ($1.0 \pm 2.5\%$), consistent with previous reports.^{10,16} A 20-min pretreatment of RPTCs with alkaline phosphatase decreased the basal adenylyl cyclase activity in membranes from RPTCs from SHRs ($15.2 \pm 2.3 \text{ pmol/mg/min}$, $P < 0.05$, paired t -test, $n = 6$). A purified catalytic subunit of PP_{2A} has been reported to decrease basal guanylyl cyclase activity.²² It is possible that the decrease in basal adenylyl cyclase activity with alkaline phosphatase treatment may reflect a change in intrinsic activity of adenylyl cyclase (agonist independent activity).³⁷ In spite of the decrease in basal adenylyl cyclase activity, alkaline phosphatase treatment enhanced the ability of the D₁R agonist, fenoldopam, to stimulate adenylyl cyclase in RPTC membranes from SHRs ($26 \pm 6\%$) (Figure 5a). Thus, dephosphorylation of the hyperphosphorylated rat D₁Rs in RPTCs from SHRs (Figure 5b) restored the sensitivity of D₁Rs to agonist stimulation.

DISCUSSION

Desensitization of many GPCRs, defined as loss of responsiveness following agonist treatment, is thought to involve largely their phosphorylation by a variety of protein kinases, including G protein-coupled receptor kinase

(GRKs).^{1,11,13–15,19,29,38,40} Agonist stimulation phosphorylates the D₁R at serine and threonine but not tyrosine residues.^{8,11,14,15,19,38,40,41} In renal tissue, the serine phosphorylation of the D₁R is carried out by GRKs, mainly by GRK4, with minor contribution by GRK2, and resulting in its desensitization.^{8,11,29} We have also reported that D₁R dephosphorylation, recycling to the cell surface membrane, and resensitization is abnormal in SHR because of impaired activity of PP_{2A}.¹⁶ Therefore, it is possible that the increased phosphorylation of the D₁R in RPTCs from SHR is caused both by increased GRK activity and decreased PP_{2A} activity. The aim of this study was to determine the effect of dephosphorylation on D₁R subcellular localization and function in RPTCs from SHR.

The quantity of phosphorylated D₁R in the basal state is greater in BBMs and renal cortex membrane, as well as in membranes of immortalized RPTCs, from SHR than from WKY rats (Figure 1). This finding is in agreement with our studies in primary cultures of RPTCs from humans with essential hypertension compared with normotensive humans.^{8,11} The similarity of the findings in the native kidney, primary culture of RPTCs in humans, and immortalized RPTCs in rats indicates that immortalization does not confer 'spurious' phenotypes, at least as far as the D₁R^{5,7,9,10,16,25–27,29} and AT₁R are concerned.⁴²

We now report that the cell surface membrane expression (determined morphologically and biochemically) of D₁Rs is decreased in immortalized RPTCs from SHR relative to WKY rats (Figure 2c), in spite of similar quantities of D₁Rs in whole cells.¹⁰ In the kidney of WKY rats, the D₁Rs are mainly located at the microvillous brush border and apical membranes, but less at the apical membranes in SHR, consistent with the studies in immortalized RPTCs (Figure 2c). The increased colocalization of D₁R with Rab5 (Figure 3) in SHR may reflect internalized D₁Rs that could not be recycled back to the apical membranes because of hyperphosphorylation of these receptors. The serine hyperphosphorylation of D₁Rs in SHR accompanied by a decrease in expression at cell surface membranes, and an increase in colocalization with Rab5 may be taken to indicate that a majority of D₁Rs in renal proximal tubules are internalized and failed to be recycled to the cell surface membrane, resulting in defective function.^{1,3,5–11,16} A similar process may explain the impaired renal D₁R function and high blood pressure associated with aging.²⁰

We utilized pharmacological and biochemical approaches to determine whether the D₁R dysfunction in immortalized RPTCs of SHR can be ameliorated. Protamine inhibits PP₁ activity but stimulates PP_{2A} activity by targeting the PP_{2A}-A subunit to interact with the PP_{2A} catalytic subunit.^{12,23,24} A concentration of protamine that has been documented to increase PP_{2A} and decrease PP₁ activity increases D₁R density on cell surface membranes and responsiveness of D₁R to agonist stimulation in SHR (Figure 3a and b). The protamine-induced change in D₁R expression may be the consequence of the resensitization of D₁Rs recruited from internalized receptors to a polar side of the cell surface.

Fenoldopam, the D₁-like agonist used in our studies, has been reported to increase the recruitment of D₁Rs to the cell surface membrane of porcine renal cells, increasing D₁R responsiveness.³⁹

To examine further the role of increased protein phosphorylation on D₁R dysfunction in SHR, membranes from immortalized RPTCs were treated with alkaline phosphatase. Alkaline phosphatase has been used to study the role of dephosphorylation in GPCR function.²¹ In the current studies, to measure adenylyl cyclase activity, membranes rather than intact cells were used. While increasing PP_{2A} activity with protamine in intact cells does not alter basal cAMP levels, basal adenylyl cyclase activity is decreased by the alkaline phosphatase treatment of RPTC membranes from SHR. Nevertheless, alkaline phosphatase treatment of membranes from immortalized RPTCs from SHR decreases the quantity of serine-phosphorylated D₁R (Figure 4b) and enhances the ability of a D₁R agonist to stimulate adenylyl cyclase activity (Figure 4a), in agreement with the results of the protamine studies. Taken together with the data using intact cells and protamine, these data strongly support the hypothesis that the hyperphosphorylation of the D₁R is responsible for the decreased D₁R activity in the SHR.

In summary, we have found increased basal levels of serine-phosphorylated D₁R in renal cortical membranes and BBMs and RPTCs from SHR. This was associated with decreased levels of cell surface membrane D₁Rs (in SHR), in spite of similar expression of D₁Rs in the whole RPTCs in WKY and SHR. Increasing protein phosphatase activity, specifically PP_{2A}, increased D₁Rs on the cell surface membrane, enabled a D₁-like agonist to alter D₁R cell surface expression, and normalized D₁R linkage to adenylyl cyclase in the SHR. The cause of the impaired PP_{2A} action in SHR is not known; however, we have reported that the regulatory PP_{2A} subunit, B56 α , is not properly targeted to the renal proximal tubular cell membrane in SHR.¹⁶ The cause of the mis-targeting of PP_{2A} B56 α remains to be determined.

MATERIALS AND METHODS

Immunoprecipitation and immunoblotting

Immunoprecipitation of serine-phosphorylated D₁Rs. Membranes from kidney cortex, BBMs, and RPTCs (0.5–1 mg protein) were incubated with 4 μ g anti-phosphoserine antibodies and protein G beads with rocking for 2 h or overnight in a cold room. The immune complexes on the beads were washed with homogenizing buffer, eluted with Laemmli buffer, and boiled for 10 min. The immunoprecipitates were then immunoblotted with polyclonal affinity-purified rabbit anti-rat D₁R antibody. The amount of protein transferred onto the nitrocellulose membrane was verified by Ponceau-S stain. All blots were visualized by ECL and quantified by densitometry, using Quantiscan, as reported.^{10,16,25–27,29} All the data from different runs were normalized so that the sum of all density units from each run was 100%.

Biotinylation of apical and basolateral membrane proteins. The cells, cultured in Transwells, were washed with Dulbecco's modified Eagle's medium /F12-serum-free medium (SFM). Cell surface

membrane proteins were biotinylated^{25,32} by adding a non-cleavable cell-impermeant biotin reagent (EZ-link sulfo-NHS-biotin) dissolved in SFM (500 µg/ml) to either the apical side (upper chamber) or basal side (lower chamber). The cells were incubated for 20 min on ice, washed, and lysed in phosphate-buffered saline containing 1% NP-40, 0.1% sodium dodecyl sulfate, 0.5% deoxycholate, and centrifuged 16 000 *g* for 10 min. The supernatants were subjected to immunoprecipitation with anti-D₁R antibody and immunoblotting with avidin-conjugated peroxidase.

Enzymatic dephosphorylation and adenylyl cyclase assay

For the dephosphorylation experiment and adenylyl cyclase assay, immortalized RPTCs from WKY and SHRs were used. The membranes were freshly prepared as described previously.^{10,16,25} The membranes were resuspended in Tris and EDTA (TE) buffer containing 2 mM MgCl₂ (TEM buffer),²⁵ and subjected to enzymatic treatment with alkaline phosphatase.^{21,22} The membranes (40 µg) were incubated with 5–10 units of alkaline phosphatase in 50 µl of reaction buffer (with the alkaline phosphatase kit) at room temperature for 20 min. Okadaic acid, a serine/threonine phosphatase inhibitor, was added (0.1 µmol/l) to stop the reaction. The membranes were assayed for adenylyl cyclase activity according to our published protocol.²⁸ Protein concentrations were determined using a protein assay kit.

Immunofluorescence microscopy

RPTC immunofluorescence staining was performed according to our previous report.²⁵ Briefly, RPTCs were grown on glass cover slips, fixed with 2% formaldehyde for 10 min at room temperature, and washed three times with phosphate-buffered saline. The cells were then stained under non-permeabilizing or permeabilizing conditions. Permeabilization was achieved by incubation with 0.1% Triton X-100 in phosphate-buffered saline buffer, for 10 min at room temperature. Some cells were pretreated with vehicle or protamine (5 µmol/l) (to increase PP_{2A} activity)^{12,23,24} in complete culture medium for 24 h prior to treatment with fenoldopam. The cells were incubated anti-D₁R antibody (1:200) followed by Alexa 488-conjugated goat anti-rabbit secondary antibody (1:500). After extensive washing, the cover slips were mounted and the fluorescence densities and images were obtained using laser confocal scanning microscopy (Olympus Fluoview FV600) with original magnification × 60 objective at an excitation wavelength of 488 nm; emission was detected at 505 nm. A total of 15 images from each cover slip (*n* = 3) were counted for quantitation of receptor internalization.⁴³

Immunohistochemical staining of rat kidney tissue

Rat kidney sections were prepared as described previously.⁴⁴ Briefly, the rat kidney was pre-flushed with an isotonic phosphate buffer and fixed with 2% glutaraldehyde through the aorta at a pressure of 140 mm Hg, and subsequently embedded in paraffin. Kidney sections were deparaffinized, rehydrated, permeabilized, and blocked with 5% goat serum. For D₁R colocalization with Rab5, the kidney sections were double-stained with specific polyclonal rabbit anti-rat D₁R and monoclonal anti-Rab5 antibodies, followed by Alexa 568-conjugated goat anti-rabbit and Alexa 488-conjugated goat anti-mouse secondary antibodies (1:500). The secondary antibodies also served as negative controls; no staining was observed using only the secondary antibodies (data not shown). The fluorescence images were obtained by laser scanning confocal microscopy, as described.²⁵

Live cell labeling for confocal imaging

Cell surface membranes of live RPTCs grown on coverslips were labeled with EZ-link sulfo-NHS-biotin.^{21,25,32} Live cells were washed once with Dulbecco's modified Eagle's medium/F12 SFM and biotin-labeled (500 µg/ml in SFM) for 20 min on ice.²⁵ The cells were washed three times with cold phosphate-buffered saline containing glycine (10 µmol/l), pH 7.0. The cells were then incubated for 10 min with avidin-conjugated CyTM 5 (far red) (1:100 dilution in SFM) on ice. The cells were fixed and subjected to dual immunofluorescence staining with an anti-rat D₁R antibodies conjugated with Alexa-488. Cover slips were washed, mounted, and subjected to confocal microscopic study as above. For CyTM5, the excitation wavelength was 650 nm; emission was detected at 670 nm.

Statistical analyses

The data are expressed as means ± s.e. Comparison within groups was made using analysis of variance (ANOVA) for repeated measures (or paired *t*-test when only two groups were compared) and comparison among groups was made using factorial ANOVA with Neuman-Keuls test (or *t*-test when only two groups were compared). Corresponding periods between two different groups were analyzed using independent *t*-test. *P* < 0.05 was considered significant.

ACKNOWLEDGMENTS

These studies were supported in part by grants from the National Institutes of Health, DK39308, DK52612, HL68686, HL074940, HL23081 (PAJ and RAF), and HL41618 (UH).

SUPPLEMENTARY MATERIAL

Supplementary text. Materials and References.

REFERENCES

- Zeng C, Sanada H, Watanabe H *et al.* Functional genomics of the dopaminergic system in hypertension. *Physiol Genomics* 2004; **19**: 233–246.
- Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. *Hypertension* 1998; **32**: 187–197.
- Albrecht FE, Drago J, Felder RA *et al.* Role of the D_{1A} dopamine receptor in the pathogenesis of genetic hypertension. *J Clin Invest* 1996; **97**: 2283–2288.
- Hollon TR, Bek MJ, Lachowicz JE *et al.* Mice lacking D5 dopamine receptors have increased sympathetic tone and are hypertensive. *J Neurosci* 2002; **22**: 10801–10810.
- Kunimi M, Seki G, Hara C *et al.* Dopamine inhibits renal Na⁺:HCO₃⁻ cotransporter in rabbits and normotensive rats but not in spontaneously hypertensive rats. *Kidney Int* 2000; **57**: 534–543.
- Nishi A, Eklöf A-C, Bertorello AM, Aperia A. Dopamine regulation of renal Na⁺, K⁺-ATPase activity is lacking in Dahl salt-sensitive rats. *Hypertension* 1993; **21**: 767–771.
- Pedrosa R, Jose PA, Soares-da-Silva P. Defective D1-like receptor-mediated inhibition of the Cl⁻/HCO₃⁻-exchanger in immortalized SHR proximal tubular epithelial cells. *Am J Physiol Renal Physiol* 2004; **286**: F1120–F1126.
- Sanada H, Jose PA, Hazen-Martin D *et al.* Dopamine-1 receptor defect in renal proximal tubular cells in essential hypertension. *Hypertension* 1999; **33**: 1036–1042.
- Hussain T, Lokhandwala MF. Renal dopamine DA₁ receptor coupling with G_s and G_{q/11} proteins in spontaneously hypertensive rats. *Am J Physiol* 1997; **272**: F339–F346.
- Xu J, Li XX, Albrecht FE *et al.* D₁ receptor, G_sα, and Na⁺/H⁺ exchanger interactions in the kidney in hypertension. *Hypertension* 2000; **36**: 395–399.
- Felder RA, Sanada H, Xu J *et al.* G protein-coupled receptor kinase 4 gene variants in human essential hypertension. *Proc Natl Acad Sci USA* 2002; **99**: 3872–3877.
- Pitcher JA, Payne ES, Csontos C *et al.* The G-protein-coupled receptor phosphatase: a protein phosphatase type 2A with a distinct subcellular

- distribution and substrate specificity. *Proc Natl Acad Sci USA* 1995; **92**: 8343–8347.
13. Carman CV, Benovic JL. G-protein-coupled receptors: turn-ons and turn-offs. *Curr Opin Neurobiol* 1998; **8**: 335–344.
 14. Tiberi M, Nash SR, Bertrand L et al. Differential regulation of dopamine D₁A receptor responsiveness by various G protein-coupled receptor kinases. *J Biol Chem* 1996; **271**: 3771–3778.
 15. Jiang D, Sibley DR. Regulation of D₁ dopamine receptors with mutations of protein kinase phosphorylation sites: attenuation of the rate of agonist-induced desensitization. *Mol Pharmacol* 1999; **56**: 675–683.
 16. Yu P, Asico LD, Eisner GM et al. Renal protein phosphatase 2A activity and spontaneous hypertension in rats. *Hypertension* 2000; **36**: 1053–1058.
 17. Efendiev R, Yudowski GA, Zwiller J et al. Relevance of dopamine signals anchoring dynamin-2 to the plasma membrane during Na⁺,K⁺-ATPase endocytosis. *J Biol Chem* 2002; **277**: 44108–44114.
 18. Adlersberg M, Hsiung SC, Glickstein SB et al. Regulation of dopamine D₁-receptor activation *in vivo* by protein phosphatase 2B (calcineurin). *J Neurochem* 2004; **90**: 865–873.
 19. Kim OJ, Gardner BR, Williams DB et al. The role of phosphorylation in D₁ dopamine receptor desensitization: evidence for a novel mechanism of arrestin association. *J Biol Chem* 2004; **279**: 7999–8010.
 20. Asghar M, Hussain T, Lokhandwala MF. Higher basal serine phosphorylation of D₁A receptors in proximal tubules of old Fischer 344 rats. *Am J Physiol Renal Physiol* 2002; **283**: F350–F355.
 21. Kim SO, Houtman JC, Jiang J et al. Growth hormone-induced alteration in ErbB-2 phosphorylation status in 3T3-F442A fibroblasts. *J Biol Chem* 1999; **274**: 36015–36024.
 22. Potter LR. Phosphorylation-dependent regulation of the guanylyl cyclase-linked natriuretic peptide receptor B: dephosphorylation is a mechanism of desensitization. *Biochemistry* 1998; **37**: 2422–2429.
 23. Swiatek W, Sugajski E, Lankiewicz L et al. Biochemical characterization of recombinant subunits of type 2A protein phosphatase overexpressed in *Pichia pastoris*. *Eur J Biochem* 2000; **267**: 5209–5216.
 24. Michelson S, Turowski P, Picard L et al. Human cytomegalovirus carries serine/threonine protein phosphatases PP1 and a host-cell derived PP2A. *J Virol* 1996; **70**: 1415–1423.
 25. Yu P, Yang Z, Jones JE et al. D₁ dopamine receptor signaling involves caveolin-2 in HEK-293 cells. *Kidney Int* 2004; **66**: 2167–2180.
 26. Albrecht FE, Xu J, Moe OW et al. Regulation of NHE3 activity by G protein subunits in renal brush-border membranes. *Am J Physiol Regul Integr Comp Physiol* 2000; **278**: R1064–R1073.
 27. Zeng C, Yang Z, Wang Z et al. Interaction of AT₁ and D₅ dopamine receptors in renal proximal tubule cells. *Hypertension* 2005; **45**: 804–810.
 28. Felder CC, Campbell T, Albrecht F, Jose PA. Dopamine inhibits Na⁺-H⁺ exchanger activity in renal BBMV by stimulation of adenylate cyclase. *Am J Physiol* 1990; **259**: F297–F303.
 29. Watanabe H, Xu J, Bengra C et al. Desensitization of human renal D₁ dopamine receptors by G protein-coupled receptor kinase 4. *Kidney Int* 2002; **62**: 790–798.
 30. O'Connell DP, Botkin SJ, Ramos SI et al. Localization of dopamine D_{1A} receptor protein in rat kidneys. *Am J Physiol* 1995; **268**: F1185–F1197.
 31. Soares-da-Silva P. Source and handling of renal dopamine: its physiological importance. *News Physiol Sci* 1994; **9**: 128–134.
 32. Zaas DW, Duncan MJ, Li G et al. Pseudomonas invasion of type I pneumocytes is dependent on the expression and phosphorylation of caveolin-2. *J Biol Chem* 2005; **280**: 4864–4872.
 33. Yang LE, Maunsbach AB, Leong PK, McDonough AA. Differential traffic of proximal tubule Na⁺ transporters during hypertension or PTH: NHE3 to base of microvilli vs. NaPi2 to endosomes. *Am J Physiol Renal Physiol* 2004; **287**: F896–F906.
 34. Zerial M, McBride H. Rab proteins as membrane organizers. *Nat Rev Mol Cell Biol* 2001; **2**: 107–117.
 35. Rosenfeld JL, Knoll BJ, Moore RH. Regulation of G-protein-coupled receptor activity by rab GTPases. *Receptors Channels* 2002; **8**: 87–97.
 36. Seachrist JL, Ferguson SS. Regulation of G protein-coupled receptor endocytosis and trafficking by Rab GTPases. *Life Sci* 2003; **74**: 225–235.
 37. Vargas GA, Von Zastrow M. Identification of a novel endocytic recycling signal in the D₁ dopamine receptor. *J Biol Chem* 2004; **279**: 37461–37469.
 38. Le Crom S, Sugamori KS, Sidhu A et al. Delineation of the conserved functional properties of D_{1A}, D_{1B}, and D_{1C} dopamine receptor subtypes in vertebrates. *Biol Cell* 2004; **96**: 383–394.
 39. Brismar H, Asghar M, Carey RM et al. Dopamine-induced recruitment of dopamine D₁ receptors to the plasma membrane. *Proc Natl Acad Sci USA* 1998; **95**: 5573–5578.
 40. Ng GY, Mouillac B, George SR et al. Desensitization, phosphorylation and palmitoylation of the human dopamine D₁ receptor. *Eur J Pharmacol* 1994; **267**: 7–19.
 41. Jackson A, Iwaszow RM, Chaar ZY et al. Homologous regulation of the heptahelical D_{1A} receptor responsiveness: specific cytoplasmic tail regions mediate dopamine-induced phosphorylation, desensitization and endocytosis. *J Neurochem* 2002; **82**: 683–697.
 42. Parenti A, Cui XL, Hopfer U et al. Activation of MAPKs in proximal tubule cells from spontaneously hypertensive and control Wistar-Kyoto rats. *Hypertension* 2000; **35**: 1160–1166.
 43. Vickery RG, von Zastrow M. Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. *J Cell Biol* 1999; **144**: 31–43.
 44. Andrews PM, Coffey AK. A technique to reduce fixation artifacts to kidney proximal tubules. *Kidney Int* 1984; **25**: 964–968.